Alnylam: Q1 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $65.9 million in its first quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 52 cents. Losses, adjusted for one-time gains and costs, were 16 cents per share.
The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 75 cents per share.
The RNA interference drug developer posted revenue of $494.3 million in the period, also beating Street forecasts. Eleven analysts surveyed by Zacks expected $421.1 million.
Alnylam shares have dropped 22% since the beginning of the year. The stock has declined 26% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY